Moody Lynn & Lieberson LLC Has $32.36 Million Holdings in Stryker Corporation (NYSE:SYK)

Moody Lynn & Lieberson LLC increased its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 25.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 86,937 shares of the medical technology company's stock after purchasing an additional 17,360 shares during the period. Stryker accounts for about 2.1% of Moody Lynn & Lieberson LLC's holdings, making the stock its 17th biggest holding. Moody Lynn & Lieberson LLC's holdings in Stryker were worth $32,362,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Mascoma Wealth Management LLC increased its holdings in shares of Stryker by 22.7% in the 4th quarter. Mascoma Wealth Management LLC now owns 146 shares of the medical technology company's stock worth $53,000 after acquiring an additional 27 shares during the period. Lindbrook Capital LLC raised its holdings in shares of Stryker by 2.0% during the fourth quarter. Lindbrook Capital LLC now owns 1,407 shares of the medical technology company's stock valued at $507,000 after buying an additional 28 shares during the last quarter. Continuum Advisory LLC raised its holdings in shares of Stryker by 5.8% during the first quarter. Continuum Advisory LLC now owns 532 shares of the medical technology company's stock valued at $198,000 after buying an additional 29 shares during the last quarter. Oakworth Capital Inc. grew its holdings in Stryker by 0.5% in the 1st quarter. Oakworth Capital Inc. now owns 6,133 shares of the medical technology company's stock worth $2,283,000 after buying an additional 29 shares in the last quarter. Finally, United Community Bank increased its position in Stryker by 3.4% in the 4th quarter. United Community Bank now owns 904 shares of the medical technology company's stock valued at $325,000 after acquiring an additional 30 shares during the period. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently weighed in on SYK. Roth Mkm lifted their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Sanford C. Bernstein set a $450.00 price objective on shares of Stryker in a report on Monday, May 5th. The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. Wall Street Zen cut Stryker from a "buy" rating to a "hold" rating in a research report on Friday, June 27th. Finally, Evercore ISI cut their price objective on Stryker from $400.00 to $390.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $427.30.

Stryker Price Performance

Stryker stock traded down $4.76 on Wednesday, reaching $391.98. The company's stock had a trading volume of 1,134,095 shares, compared to its average volume of 1,344,817. Stryker Corporation has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a market cap of $149.61 billion, a price-to-earnings ratio of 52.97, a PEG ratio of 2.98 and a beta of 0.91. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.64. The business's fifty day moving average price is $381.08 and its 200 day moving average price is $375.74.

Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 EPS for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 12.31% and a return on equity of 23.74%. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the prior year, the firm earned $2.50 EPS. The company's revenue was up 11.9% on a year-over-year basis. Equities analysts expect that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.86%. Stryker's payout ratio is 45.41%.

Insider Activity at Stryker

In other news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director directly owned 3,417,326 shares in the company, valued at $1,288,195,208.96. This trade represents a 5.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.20% of the company's stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.